[go: up one dir, main page]

WO2011088474A3 - Sulindac et dérivés de sulindac et leurs applications aux infections - Google Patents

Sulindac et dérivés de sulindac et leurs applications aux infections Download PDF

Info

Publication number
WO2011088474A3
WO2011088474A3 PCT/US2011/021587 US2011021587W WO2011088474A3 WO 2011088474 A3 WO2011088474 A3 WO 2011088474A3 US 2011021587 W US2011021587 W US 2011021587W WO 2011088474 A3 WO2011088474 A3 WO 2011088474A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulindac
infection
derivatives
uses related
methenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/021587
Other languages
English (en)
Other versions
WO2011088474A2 (fr
Inventor
Natalie Mcdonald
James Murray
Thomas Hodge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PERRYMAN DAVID
Zirus Inc
Original Assignee
PERRYMAN DAVID
Zirus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PERRYMAN DAVID, Zirus Inc filed Critical PERRYMAN DAVID
Publication of WO2011088474A2 publication Critical patent/WO2011088474A2/fr
Publication of WO2011088474A3 publication Critical patent/WO2011088474A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Les présentes compositions et méthodes sont liées à l'emploi de ((R-S(=O)0-2-R'0,1-arylène)-méthényl-indén-3-yl)acétyles dans la réduction d'une infection provoquée par un pathogène.
PCT/US2011/021587 2010-01-15 2011-01-18 Sulindac et dérivés de sulindac et leurs applications aux infections Ceased WO2011088474A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33606910P 2010-01-15 2010-01-15
US61/336,069 2010-01-15
US34359410P 2010-04-30 2010-04-30
US61/343,594 2010-04-30
US36980810P 2010-08-02 2010-08-02
US61/369,808 2010-08-02

Publications (2)

Publication Number Publication Date
WO2011088474A2 WO2011088474A2 (fr) 2011-07-21
WO2011088474A3 true WO2011088474A3 (fr) 2011-12-29

Family

ID=44305023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/021587 Ceased WO2011088474A2 (fr) 2010-01-15 2011-01-18 Sulindac et dérivés de sulindac et leurs applications aux infections

Country Status (1)

Country Link
WO (1) WO2011088474A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402821B2 (en) 2012-08-13 2016-08-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for treatment of cystic fibrosis
WO2017083971A1 (fr) * 2015-11-16 2017-05-26 University Of Manitoba Compositions et méthodes pour le traitement de la grippe
PL237474B1 (pl) 2017-05-04 2021-04-19 Wyzsza Szkola Medyczna W Bialymstoku Nowe zastosowanie kwasu 2-[(3Z)-6-fluoro-2-metylo-3-[(4-metylosulfinylofenylo) metylideno]inden-1-ylo] octowego
WO2021202014A1 (fr) * 2020-03-30 2021-10-07 Applied Biology, Inc. Anti-androgène ou antagoniste du récepteur des androgènes pour le traitement d'une infection respiratoire virale
US11338010B2 (en) 2020-03-30 2022-05-24 Suzhou Kintor Pharmaceuticals, Inc. Systems, methods, and kits for diagnostics and treatment of viral respiratory infection
WO2021255218A1 (fr) 2020-06-19 2021-12-23 Charité - Universitätsmedizin Berlin Combinaison pharmaceutique comprenant un protonophore antiviral et un inhibiteur de sérine protéase
CN119587523B (zh) * 2024-12-18 2025-10-03 江汉大学 舒林酸酯基三氟甲基硒在制备抗肠道病毒药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049859A1 (fr) * 1998-03-28 1999-10-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combinaison de dfmo et de sulindac dans la chimioprevention du cancer
US6232312B1 (en) * 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US20030004143A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the female reproductive tract

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232312B1 (en) * 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
WO1999049859A1 (fr) * 1998-03-28 1999-10-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combinaison de dfmo et de sulindac dans la chimioprevention du cancer
US20030004143A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the female reproductive tract

Also Published As

Publication number Publication date
WO2011088474A2 (fr) 2011-07-21

Similar Documents

Publication Publication Date Title
WO2010003133A3 (fr) Modulateurs de cdk
MX2010004493A (es) Compuestos de tropano.
IN2012DN00736A (fr)
AU2013291345B2 (en) Composition for controlling plant disease and application therefor
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
IN2012DN00692A (fr)
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
WO2011153157A3 (fr) Inhibiteurs benzoquinolone de vmat2
WO2014072017A8 (fr) Matériaux pour dispositifs électroniques
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
WO2011088474A3 (fr) Sulindac et dérivés de sulindac et leurs applications aux infections
WO2012065019A3 (fr) Inhibiteurs pyridopyrimidinone de p13k alpha
BR112012011328A2 (pt) inibidores de akt
WO2010150211A3 (fr) Utilisation de dérivés d'indoles dans le traitement du cancer
AU2008246443A8 (en) 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
MX2012001620A (es) Derivados de n1-acil-5-fluoropirimidinona.
WO2014121055A3 (fr) Modulateurs flap
WO2011069045A3 (fr) Synthèse de d'inhibiteurs du protéasome syrbactine
EP3546025A3 (fr) Utilisation d'oléogels dans des compositions absorbant les rayons uv
WO2011103524A8 (fr) Tétrapeptides cycliques et leurs applications thérapeutiques
WO2012092288A3 (fr) Compositions et procédés d'utilisation des formes cristallines d'analogues de wortmannine
WO2011128699A3 (fr) Procédés inédits
TN2012000381A1 (en) 2-aldoximino-5-fluoropyrimidine derivatives
WO2009078036A3 (fr) Procédé et produit intermédiaire du létrozole
WO2010009029A3 (fr) Procédés pour la préparation de composés azole

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11733543

Country of ref document: EP

Kind code of ref document: A2